KEAP1 and osteosarcoma: In an attempt to winnow down the list of hits to at least one FDA-approved clinical candidate for NGLY1 deficiency, a total of 91 repurposing hits and novel suppressors from both worm and fly screens were cross-tested in a Keap1-NRF2 activation assay in the U2OS osteosarcoma cell line.